Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.

Journal of virology - 1 Mar 2014

Zapata Juan C, Goicochea Marco, Nadai Yuka, Eyzaguirre Lindsay M, Carr Jean K, Tallon Luke J, Sadzewicz Lisa, Myers Garry, Fraser Claire M, Su Qi, Djavani Mahmoud, Lukashevich Igor S, Salvato Maria S

Abstract excerpt

The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by 40% in nucleic acid sequence. In our previous studies, ML29 elicited sterilizing immunity against Lassa virus challenge in guinea pigs and marmosets and virus-specific cell-mediated immunity in both simian immunodeficiency virus (SIV)-infected and uninfected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Callithrix
Share to Chlorocebus aethiops

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity, Cellular

Share to Macaca mulatta

Share to Mice, Inbred CBA

Share to Vaccines, Attenuated

Share to Vero Cells

Share to Viral Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 24335292
DOI: 10.1128/JVI.03035-13
PMCID: PMC3957910

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.PMID 24335292Read ↗

Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complexSemantic proximity Read ↗

General Molecular Strategy for Development of Arenavirus Live-Attenuated VaccinesSemantic proximity Read ↗

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigsSemantic proximity Read ↗

Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events.Semantic proximity Read ↗

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and developmentSemantic proximity Read ↗

Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and AttenuationSemantic proximity Read ↗

A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous GlycoproteinsSemantic proximity Read ↗

Lassa virus diversity and feasibility for universal prophylactic vaccineSemantic proximity Read ↗

Viral Pathogens and ImmunityMutations Affecting the UL21 Gene Contribute to Avirulence of Pseudorabies Virus Vaccine Strain BarthaSemantic proximity Read ↗

A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic RegionSemantic proximity Read ↗

The Mucosal Barrier and Anti-Viral Immune Responses can Eliminate Portions of the Viral Population during Transmission and Early Viral GrowthSemantic proximity Read ↗

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shotSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.